Tevogen Bio has entered a partnership with BioCentriq, a New Jersey based cell and gene therapy development and manufacturing center, to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment.

Both partners will collaborate at BioCentriq’s state-of-the art GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells. The teams will leverage processes and technology required to ensure quality standards are met in the large scale manufacturing of Tevogen’s clinical grade, allogeneic T-cell therapy.

“Our team of experts will work collaboratively with Tevogen to apply best practices, advanced technologies and proven analytical methods to prepare them for clinical trials and beyond,” said Haro Hartounian, Ph.D., senior vice-president, and general manager of BioCentriq. “We are proud to partner with a New Jersey based biotechnology company that is advancing highly promising investigational curative therapy by leveraging lab-grown virus-specific t-lymphocytes to recognize and destroy COVID-19-infected cells.”

Tevogen’s IND application for its antigen specific T cell therapy is currently under review by the U.S. FDA. In the upcoming trials, Tevogen will study its highly enriched COVID-19 specific CD8+ T cells, TVGN-489, for the drug’s safety and ability to recognize and eliminate COVID-19 infected cells, essentially curing a patient of the virus.